MTNB News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MT

Volume

23.91K

Next Earnings

November 9th

Loading chart

MT

MTNBMatinas BioPharma Holdings, Inc.

MTNB

Pay with—

Available Balance0.00

MT

Mkt Cap

$2.4M

Volume

23.91K

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsMatinas BioPharma received a notice from NYSE American on August 31, 2026, stating the company is not in compliance with continued listing standards due to stockholders' equity of $1.8 million (below the required $2.0 million threshold) and losses in five consecutive fiscal years. The company submitted a compliance plan accepted by NYSE American with a deadline of October 2, 2027. Shares will continue trading during the plan period, but delisting proceedings may be initiated if compliance is not achieved.GlobeNewswire Inc. · Sep 4, 2026

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain ComplianceMatinas BioPharma received a notice from NYSE American on June 24, 2026, regarding non-compliance with continued listing standards due to insufficient stockholders' equity relative to accumulated losses. The company submitted a compliance plan and has been granted until October 2, 2027, to regain compliance. Failure to meet standards by the deadline could result in delisting proceedings.GlobeNewswire Inc. · Jun 26, 2026

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access ProgramBEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis (flesh-eating disease) that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales. This patient was treated at New York Presbyterian/Weill Cornell Medical Center and was discharged after just six weeks of treatment with MAT2203, Matinas’ oral formulation of the potent antifungal amphotericin B. The patient was treated under Matinas’ Compassionate/ Expanded Use Access Program by Sharan Yadav, MD, Infectious Disease Fellow.GlobeNewswire Inc. · Jun 24, 2024

Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. PerlinMatinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. PerlinGlobeNewswire Inc. · Jun 13, 2024

New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston.GlobeNewswire Inc. · May 16, 2024

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateRecent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025GlobeNewswire Inc. · May 9, 2024

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).GlobeNewswire Inc. · May 2, 2024

Matinas BioPharma Prices $10 Million Registered Direct OfferingBEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (“Matinas BioPharma” or the “Company”), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today announced it has entered into securities purchase agreements with healthcare-focused institutional investors for the purchase and sale of 33,333,334 shares of common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate of 33,333,334 shares of common stock, at a combined offering price of $0.30 per share and accompanying warrant, pursuant to a registered direct offering. The warrants will have an exercise price of $0.35 per share, will be exercisable commencing six months from the date of issuance and will expire five and one-half years following the date of issuance.GlobeNewswire Inc. · Apr 3, 2024

Matinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateClear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussionsGlobeNewswire Inc. · Mar 27, 2024

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationDaily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxelGlobeNewswire Inc. · Mar 25, 2024

to start trading

MT

MTNBMatinas BioPharma Holdings, Inc.

MTNB

Pay with—

Available Balance0.00

Your PositionYou don't own any MTNB yet.

Related Tickers

Earnings